Get the Stockscreener App
4.93
1.00%
-0.05
After Hours:
4.93
Lifecore Biomedical Inc stock is traded at $4.93, with a volume of 154.27K.
It is down -1.00% in the last 24 hours and down -5.74% over the past month.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
See More
Previous Close:
$4.98
Open:
$4.98
24h Volume:
154.27K
Relative Volume:
0.48
Market Cap:
$184.92M
Revenue:
$147.12M
Net Income/Loss:
$-33.88M
P/E Ratio:
-4.6409
EPS:
-1.0623
Net Cash Flow:
$2.63M
1W Performance:
+12.05%
1M Performance:
-5.74%
6M Performance:
-35.47%
1Y Performance:
-26.09%
1-Day Range:
$4.91
$5.15
1-Week Range:
$4.22
$5.15
52-Week Range:
$3.625
$8.9799
Lifecore Biomedical Inc Stock (LFCR) Company Profile
Name
Lifecore Biomedical Inc
Sector
Phone
(952) 368-4300
Address
3515 LYMAN BOULEVARD, CHASKA
Compare LFCR vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LFCR
Lifecore Biomedical Inc
|
4.93 | 186.80M | 147.12M | -33.88M | 2.63M | -1.0623 |
TAK
Takeda Pharmaceutical Co Adr
|
16.25 | 52.07B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.29 | 41.28B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.07 | 39.78B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
81.32 | 33.57B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
568.43 | 24.02B | 3.17B | 1.29B | 1.01B | 27.09 |
Lifecore Biomedical Inc Stock (LFCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Sep-04-25 | Initiated | KeyBanc Capital Markets | Sector Weight |
| May-21-25 | Initiated | William Blair | Outperform |
| Sep-05-24 | Initiated | Craig Hallum | Buy |
| Aug-28-24 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Mar-20-23 | Downgrade | Stephens | Overweight → Equal-Weight |
View All
Lifecore Biomedical Inc Stock (LFCR) Latest News
LFCR Q1 2026 Earnings: Wider Loss Than Expected Despite Positive Stock ReactionGlobal Trading Community - Newser
Lifecore Biomedical to Participate in William Blair 46th Annual Growth Stock Conference - Sahm
LFCR Stock Price, Quote & Chart | LIFECORE BIOMEDICAL INC (NASDAQ:LFCR) - ChartMill
Lifecore CEO, CFO to meet investors at June 2-4 Chicago conference - Stock Titan
Lifecore Biomedical (LFCR) Q1 2026 Earnings Miss by Significant: Key TakeawaysCollaborative Trading Signals - Newser
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates C - GuruFocus
Lifecore targets 12% revenue CAGR through 2029 as midterm pipeline milestones shift - MSN
Lifecore reaffirms 2026 guidance of $120M-$125M revenue and $20.5M-$25M adjusted EBITDA while targeting 12% revenue CAGR by 2029 - MSN
Lifecore Biomedical to Participate at CDMO Live Europe - The Manila Times
TradingKey - tradingkey.com
The sustainable advantages Lifecore Biomedical (LFCR) is developing (+0.42%) 2026-05-10Fast Rising Stocks - newser.com
Number of shareholders of Lifecore Biomedical, Inc. – NASDAQ:LFCR - TradingView
Lifecore Biomedical (LFCR) price target decreased by 25.71% to 6.63 - MSN
LFCR Lifecore Biomedical shares slide 3.83% as Q1 2026 earnings miss estimates by 75.7% despite modest revenue growth.Social Momentum Signals - newser.com
The steady strength in Lifecore Biomedical (LFCR) story (Softens) 2026-05-08Company Analysis - newser.com
Lifecore Biomedical Q1 2026 Earnings Call Transcript - Sahm
Barrington Maintains Lifecore Biomedical(LFCR.US) With Buy Rating, Maintains Target Price $6 - Moomoo
MSN Money - MSN
Lifecore Biomedical: Q1 Earnings Snapshot - theheraldreview.com
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore - TMX Newsfile
Lifecore Biomedical, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:LFCR) 2026-05-06 - Seeking Alpha
Lifecore Biomedical Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Keybanc Initiates Coverage of Lifecore Biomedical (LFCR) with Sector Weight Recommendation - MSN
Lifecore Biomedical, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Lifecore Biomedical Q1 Earnings Call Highlights - Yahoo Finance
LFCR: Revenue fell 34% in Q1 2026, but cost controls and new programs support reaffirmed 2026 guidance - TradingView
Lifecore Biomedical 1Q 2026: Revenue $23.19M, EPS ($0.43) — 10-Q Summary - TradingView
Lifecore (NASDAQ: LFCR) posts 34% revenue drop and high debt load - Stock Titan
Lifecore Biomedical (LFCR) Q1 2026 revenue drops but 2026 outlook reaffirmed - Stock Titan
Lifecore Biomedical Reports Financial Results for the First Quarter Ended March 31, 2026, and Provides Corporate Update - The Manila Times
Lifecore Biomedical Q1 revenue falls 34%, misses analyst estimates - TradingView
Lifecore lands 3 new transfer programs while cutting operating costs - Stock Titan
Lifecore Biomedical to Report Financial Results for the First Quarter Ended March 31, 2026, on May 6, 2026 - The Manila Times
Before the bell May 6, Lifecore releases Q1 results, holds 8 a.m. webcast - Stock Titan
Barrington Maintains Lifecore Biomedical(LFCR.US) With Buy Rating, Raises Target Price to $6 - Moomoo
Laughing Water Capital’s Insights on Lifecore Biomedical (LFCR) - Insider Monkey
[DEF 14A] LIFECORE BIOMEDICAL, INC. DE Definitive Proxy Statement - Stock Titan
Lifecore Biomedical Inc Stock (LFCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.92%
4.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):